$750,000 EBITDA Medical Device Company in Midwest

XYMF1Z - $750,000 EBITDA Medical Device Company in Midwest Seeking Equity Partner to Scale

Company Overview
Broker is proud to be the exclusive representative of a Medical Device Manufacturer and Distributor for sale. This opportunity involves the sale of a well-established therapeutic technology company specializing in FDA-cleared Class IV laser and shockwave therapy equipment. Headquartered in the Midwest, the company provides advanced, non-invasive medical devices to a broad customer base of healthcare professionals across North America.

Founded by a seasoned healthcare professional with decades of clinical experience, the company has rapidly evolved into a recognized innovator in the field of therapeutic technology. Under new ownership since 2023, the business is focused on expanding its direct sales infrastructure, optimizing distributor partnerships, and growing market share through both domestic and international channels.

With high product margins, a scalable team structure, and over 500 active customers, this business is well-positioned for accelerated growth under new leadership. The current owners are open to remaining involved post-transaction, making this an ideal opportunity for strategic or financial buyers seeking expansion in the medical device or healthcare technology sectors.

Key Highlights:
Established brand with clinical credibility and FDA-cleared products
Over 500 active customers, with repeat purchase behavior
Lean operating structure with 4 employees and 2 independent contractors
High-margin, cash-based revenue model supported by external financing partners
Ongoing buildout of a direct sales channel to increase profitability and control
Renewed regional distributor network targeting higher-quality partners
Significant growth potential via product expansion, geographic diversification, and potential entry into recurring revenue models
Financial Highlights

The company generated nearly $1.9 million in revenue in 2024, with a net adjusted EBITDA of $701,000 since the new owners took over the company in the last quarter of 2023. It is now on track to finish 2025 with $2.5 Million in Revenue and $750,000 in net adjusted EBITDA.

The business is currently on a modest upward growth trajectory as new sales strategies and infrastructure investments take hold. The company carries no outstanding liabilities, lawsuits, or tax issues.

Reason for Sale

The owners are seeking a strategic/capital partner to assist them in scaling company to the next level. To accelerate growth, the owners are open to selling majority stake plus an earn out in their company while retaining significant equity to continue growing the company.

Asking Price
After a thorough analysis of market dynamics and comparable transactions, American Healthcare Capital has established a fair market valuation of $7,500,000 for the company—reflecting both its current performance and future growth potential. The asking price excludes cash, inventory, accounts receivables, working capital and any real estate properties.